TYRP1 and hydrops fetalis: This study shows for the first time that ESHF patient candidates for LVAD implant present higher expression levels of CatB and CatL as well as their specific inhibitors, CysB and CysC, compared to less severe HF patients undergoing medical therapy (HT group).